Rising incidence of sepsis worldwide, growing prevalence of disease and advancements in diagnostics market along with rising awareness among health professionals is some of the significant factor driving the global sepsis diagnostics market.
Sepsis is a life-threatening condition resulting from the immune response of the body to an infection, and timely and correct diagnosis would help improve the prognosis of sepsis patients.
The increasing prevalence of sepsis worldwide is attributed to an increase in incidence of infections, ageing population and rising burden of chronic diseases. Rapid and accurate detection enabled by molecular diagnostics and point-of-care testing is driving growth in the market.
This means the Compounded Annual Growth Rate(CAGR) is approximately 7.9% 2035. The Market will further be increasing from USD 655.7 Million in 2025 to USD 1,402.7 Million in 2035.
Key Market Metrics
| Metric | Value |
|---|---|
| Market Size in 2025 | USD 655.7 Million |
| Projected Market Size in 2035 | USD 1,402.7 Million |
| CAGR (2025 to 2035) | 7.9% |
The sepsis diagnostics market share in North America is significant, owing to the state-of-the-art healthcare infrastructure, high awareness levels, and substantial research & development spending. For example, the United States has the highest sepsis cases globally which results in the growing demand for efficient diagnostics solutions.
Additionally, the region is experiencing the growth of the market owing to the presence of major market players and the adoption of innovative technologies.
The European sepsis diagnostics market is expanding at a rapid pace owing to the increasing healthcare expenditure and very high prevalence of early disease detection. Germany, France, and the UK, for example, are taking the lead with diagnostic tools and treatment protocols to better tackle sepsis.
Data are also behind partnerships between research institutions and healthcare providers that contextualize and disseminate novel diagnostic approaches.
The Asia-Pacific region is projected to record the fastest CAGR during the forecast period, on the back of rising incidence of sepsis, improving healthcare infrastructure and increasing awareness regarding sepsis. Countries, like, China, Japan and India are also investing towards up gradation of their healthcare investment that is widening the arena of adoption of advanced diagnostic technologies.
In addition, the growing pathogen population, and rising prevalence of infectious disease in this region are expected to drive the demand for effective sepsis diagnostics.
Delayed Detection, High Testing Costs, and Variability in Clinical Practices
Early symptoms are not specific, leading to delays in diagnosis and treatment initiation, as symptoms of early stage disease may appear similar to those of other infections, are some of the key challenges for the sepsis diagnostics market.
Sepsis is still an acute condition that has high mortality and morbidity even after the algorithm is put into place due to the fact that diagnosis is often made after the gold treatment window has passed despite improvements to medicine.
Rapid diagnostic tools are often limited and high costs of molecular or biomarker-based testing limit uptake, especially in resource-poor settings. Second there are differences in clinical workflows and decision making processes between hospitals and regions, which reduces the uniformity of sepsis diagnosis and treatment.
Point-of-Care Testing, Biomarker Innovation, and AI-Powered Decision Support
The sepsis diagnostics market is growing owing to increasing global awareness regarding sepsis as a medical emergency, especially post COVID-19 pandemic. There is growing need for real time, highly sensitive diagnostic tools that can separate out sepsis from other inflammatory syndromes.
Opportunities increasing for point-of-care testing (POCT) and multiplex biomarker panels detecting combinations of procalcitonin (PCT), IL-6, C-reactive protein (CRP) and host gene expression profiles Innovations in AI-based clinical decision support systems (CDSS) are also progressing rapidly to assist physicians with interpreting complex diagnostic data and shortening the diagnostic delay.
Integration into electronic health records (EHRs) and automated alert systems is also enhancing sepsis identification and management in emergency and ICU environments.
The period from 2020 to 2024 saw increased access to hospital-acquired infections and secondary sepsis diagnostics as the COVID-19 pandemic led to higher rates of ICU admissions, necessitating additional investment in rapid diagnostics.
During this period, growth was especially apparent in blood culture alternatives, antimicrobial resistance testing, and host response assays. Yet its adoption at smaller healthcare centers was hampered by cost and training barriers. 2035: during this time frame, the market will evolve to integrated sepsis response platforms that bring together diagnostics, predictive analytics, and use of automated early warning systems.
Molecular point-of-care platforms, next-generation sequencing (NGS) and host transcriptomic profiling will become increasingly used for rapid detection of sepsis and directed treatment. Public health policies and hospital accreditation standards will drive adoption of real-time sepsis screening protocols.
Market Shifts: A Comparative Analysis 2020 to 2024 vs. 2025 to 2035
| Market Shift | 2020 to 2024 Trends |
|---|---|
| Regulatory Landscape | Expansion of emergency use authorizations and WHO guidelines |
| Consumer Trends | Focused on hospital-based blood culture testing and biomarker kits |
| Industry Adoption | Used primarily in ICUs and emergency departments |
| Supply Chain and Sourcing | Dependent on centralized lab networks |
| Market Competition | Dominated by IVD and clinical diagnostics firms |
| Market Growth Drivers | Driven by hospital-acquired infections and mortality prevention mandates |
| Sustainability and Environmental Impact | Low focus on test kit waste and single-use plastics |
| Integration of Smart Technologies | Use of alert systems and lab automation |
| Advancements in Diagnostic Tools | Improvements in blood culture time and biomarker sensitivity |
| Market Shift | 2025 to 2035 Projections |
|---|---|
| Regulatory Landscape | Establishment of mandatory hospital sepsis protocols and diagnostic accuracy benchmarks |
| Consumer Trends | Demand for non-invasive, POCT-based sepsis screens and EHR-integrated alerts |
| Industry Adoption | Broader use in ambulatory settings, urgent care, and pre-hospital triage |
| Supply Chain and Sourcing | Shift toward decentralized diagnostics, mobile test units, and cloud-based reporting |
| Market Competition | Entry of AI-health startups, wearable diagnostics companies, and NGS developers |
| Market Growth Drivers | Accelerated by value-based care models, remote diagnostics, and infection control reforms |
| Sustainability and Environmental Impact | Increased demand for recyclable diagnostic components and sustainable packaging |
| Integration of Smart Technologies | Expansion into AI-driven triage, predictive analytics, and smart monitoring dashboards |
| Advancements in Diagnostic Tools | Innovation in rapid pathogen ID panels, sepsis transcriptomics, and lab-on-a-chip devices |
The USA is the largest market for sepsis diagnostics products, due to high healthcare expenditure, clinical awareness, and widespread implementation of early warning systems and infection control protocols. Multi-analyte panels and real-time CDSS platforms increasingly adopted in the critical care environment.
| Country | CAGR (2025 to 2035) |
|---|---|
| USA | 8.0% |
NHS-led initiatives in the UK are encouraging early diagnosis by implementing standardized screening tools and accelerating the procurement of diagnostics. Collaborations across schools, biotech companies, and public hospitals are speeding the rollout of disease type-specific, AI-enhanced sepsis detection platforms.
| Country | CAGR (2025 to 2035) |
|---|---|
| UK | 7.8% |
EU countries are still investing in hospital digitization, infection surveillance and antimicrobial stewardship, driving growth in sepsis diagnostics. Integrated diagnostic workflows and next-gen PCR panels are driving an increase in treatment timelines across Germany, France and the Netherlands.
| Region | CAGR (2025 to 2035) |
|---|---|
| EU | 7.9% |
The expansion in the market is being maneuvered by Japan’s sophisticated hospital systems and a focus on the early detection of infections. Growing need for host biomarkers testing, portable diagnostics, and low-volume blood sampling kits is bolstering growth across tertiary and secondary hospitals.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 7.9% |
South Korea is adopting solutions for sepsis diagnostics in light of smart hospital projects and AI-based infection control platforms. Government support for biotech R&D and emergency response preparedness is an important driver for the demand for rapid sepsis detection technologies across public and private healthcare networks.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 8.0% |
The growing need for rapid diagnosis in life-threatening infections together with the consensus of early detection and intervention impact the sepsis diagnostics market. Sepsis is associated with high mortality worldwide and rapid diagnostics are critical in the timely initiation of therapy. On the basis of product type, diagnostic instruments and automated methods are highly used.
Access to these segments results in faster pathogen detection, antimicrobial resistance profiling, and data-driven decision-making all of which play important roles in improving clinical outcomes.Their use in automated and instrument-based diagnostics to support sepsis care protocols in acute and emergency settings is increasingly pivotal for global healthcare systems striving to reduce ICU stays, lower mortality rates and combat antimicrobial resistance.
| Product Type | Market Share (2025) |
|---|---|
| Instrument | 64.2% |
Diagnostics account for the sepsis diagnostics market, owing to the rapid identification that instruments can offer for pathogens, biomarkers, and antibiotic susceptibility to provide results within hours. These platforms shorten diagnostic delays and inform clinicians earlier to make treatment decisions in emergent and intensive care settings.
The prominent technologies used are PCR-based analyzers, immunoassay systems, and blood culture instruments (with continuous monitoring). Instruments enable multiplex testing, reducing the need for repeated sampling, and increasing throughput in high-volume hospital labs.
Other emerging point-of-care (POC) devices allow rapid lactate and procalcitonin-testing at the bedside. These functionalities lead to accelerated triage and risk stratification for patients who come in with signs of sepsis.
Although blood culture media is still crucial for microbial growth and phenotypic confirmation, instruments dominate with respect to diagnostic speed and are promoted predominantly in protocol-driven hospitals where early goal-directed therapy is a high priority.
Automated diagnostics account for a dominant share of the sepsis diagnostics market owing to their penetration in automating the laboratory processes, improving the accuracy of detection, and offering quicker clinical insights.
Such systems mitigate risks of human error, make standardized values available to all approvers and provide seamless integration to electronic health records (EHRs) for the clinician’s response.
Automation enables fast sample processing, round-the-clock lab operation, and smart alert systems monitoring for sudden critical values. In recent years, many systems have been developed using machine learning algorithms to predict early sepsis using the trends in biomarker data and vitals of a patient.
Automated platforms are scaled for the needs of a mass population, offering infection control benefits, as well as supporting antimicrobial stewardship initiatives, and are therefore a preferred of hospitals. These technologies help decrease turnaround time from days to hours, a crucial factor in sepsis survival.
While conventional modalities such as manual microscopy and culture approaches remain important confirmatory tools, they are being increasingly augmented, and in some cases, supplanted, by automated diagnostics for front-line screening and real-time decision-making.
Technological innovations in sepsis diagnostics are being embraced within an exhaustive range of end-users like emergency departments, ICUs, and clinical laboratories that are focused on rapid detection, antimicrobial stewardship, and infection-related patient results.
Increased sepsis-related mortality and rapid evolution of global prioritization for rapid diagnostic tools will promote innovation in molecular assay, host-response biomarker, and AI-powered decision support interface.
Fortunes are being spent on point-of-care (POC) testing, multiplex PCR platforms, and integrated digital triage technologies. Speed-to-result, diagnostic accuracy, and antibiotic resistance management are key focus areas for diagnostics leaders and precision medicine startups alike.
Market Share Analysis by Key Players & Sepsis Diagnostics Providers
| Company Name | Estimated Market Share (%) |
|---|---|
| bioMérieux SA | 14-18% |
| Roche Diagnostics | 12-16% |
| Thermo Fisher Scientific Inc. | 10-14% |
| Danaher Corporation (Beckman Coulter) | 8-12% |
| Immunexpress Inc. | 6-9% |
| Other Sepsis Diagnostic Developers | 30-40% |
| Company Name | Key Offerings/Activities |
|---|---|
| bioMérieux SA | In 2024 , launched the VITEK® REVEAL system for rapid antimicrobial susceptibility testing in bloodstream infections; in 2025 , expanded its VIDAS® BRAHM S PCT assay for early sepsis risk stratification. |
| Roche Diagnostics | Released cobas® SeptiScore Panel in 2024 for differentiating bacterial vs. viral sepsis causes; in 2025 , introduced AI-powered sepsis alert integration for hospitals using cobas® Liat platforms. |
| Thermo Fisher Scientific Inc. | Launched a high-sensitivity multiplex qPCR assay for sepsis pathogen panels in 2024 ; in 2025 , developed a host-response biomarker index based on gene expression profiling. |
| Danaher Corporation (Beckman Coulter) | In 2024 , added monocyte distribution width (MDW) to routine CBC workflow for early sepsis screening; in 2025 , integrated automated sepsis flags into hematology analyzers. |
| Immunexpress Inc. | Commercialized SeptiCyte® RAPID globally in 2024 for use with Biocartis’ Idylla™ platform; in 2025 , initiated clinical deployment of host gene signature testing at the point of care. |
Key Market Insights
bioMérieux SA (14-18%)
bioMérieux remains a global leader in sepsis diagnostics with deep expertise in pathogen identification and PCT-based infection monitoring. Its 2024 to 2025 portfolio upgrades enhance early sepsis detection and treatment optimization.
Roche Diagnostics (12-16%)
Roche focuses on host-response profiling and AI-powered clinical workflows. Its 2024 to 2025 diagnostics tools improve differentiation and enable automated, actionable insights at the hospital bedside.
Thermo Fisher Scientific Inc. (10-14%)
Thermo Fisher delivers pathogen and immune response solutions through molecular diagnostics. Its 2025 advancements in sepsis gene expression profiling move diagnostics toward precision-based sepsis care.
Danaher Corporation (Beckman Coulter) (8-12%)
Danaher brings sepsis screening to routine lab testing. The MDW parameter and 2025 automation enhancements make early detection feasible across a broader spectrum of care settings.
Immunexpress Inc. (6-9%)
Immunexpress pioneers host-response diagnostics with the SeptiCyte® platform. Its 2024 to 2025 expansion into point-of-care genomics positions it at the forefront of rapid, non-pathogen-specific sepsis detection.
Other Key Players (30-40% Combined)
Numerous diagnostics firms and medtech innovators are improving speed, sensitivity, and clinical integration of sepsis detection. These include:
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Product Type, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Method, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by Pathogen , 2018 to 2033
Table 5: Global Market Value (US$ Million) Forecast by Technology, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Product Type, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by Method, 2018 to 2033
Table 9: North America Market Value (US$ Million) Forecast by Pathogen , 2018 to 2033
Table 10: North America Market Value (US$ Million) Forecast by Technology, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by Product Type, 2018 to 2033
Table 13: Latin America Market Value (US$ Million) Forecast by Method, 2018 to 2033
Table 14: Latin America Market Value (US$ Million) Forecast by Pathogen , 2018 to 2033
Table 15: Latin America Market Value (US$ Million) Forecast by Technology, 2018 to 2033
Table 16: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 17: Europe Market Value (US$ Million) Forecast by Product Type, 2018 to 2033
Table 18: Europe Market Value (US$ Million) Forecast by Method, 2018 to 2033
Table 19: Europe Market Value (US$ Million) Forecast by Pathogen , 2018 to 2033
Table 20: Europe Market Value (US$ Million) Forecast by Technology, 2018 to 2033
Table 21: Asia Pacific Excluding Japan Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: Asia Pacific Excluding Japan Market Value (US$ Million) Forecast by Product Type, 2018 to 2033
Table 23: Asia Pacific Excluding Japan Market Value (US$ Million) Forecast by Method, 2018 to 2033
Table 24: Asia Pacific Excluding Japan Market Value (US$ Million) Forecast by Pathogen , 2018 to 2033
Table 25: Asia Pacific Excluding Japan Market Value (US$ Million) Forecast by Technology, 2018 to 2033
Table 26: Japan Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 27: Japan Market Value (US$ Million) Forecast by Product Type, 2018 to 2033
Table 28: Japan Market Value (US$ Million) Forecast by Method, 2018 to 2033
Table 29: Japan Market Value (US$ Million) Forecast by Pathogen , 2018 to 2033
Table 30: Japan Market Value (US$ Million) Forecast by Technology, 2018 to 2033
Table 31: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 32: Middle East and Africa Market Value (US$ Million) Forecast by Product Type, 2018 to 2033
Table 33: Middle East and Africa Market Value (US$ Million) Forecast by Method, 2018 to 2033
Table 34: Middle East and Africa Market Value (US$ Million) Forecast by Pathogen , 2018 to 2033
Table 35: Middle East and Africa Market Value (US$ Million) Forecast by Technology, 2018 to 2033
Figure 1: Global Market Value (US$ Million) by Product Type, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Method, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Pathogen , 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Technology, 2023 to 2033
Figure 5: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 6: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 9: Global Market Value (US$ Million) Analysis by Product Type, 2018 to 2033
Figure 10: Global Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033
Figure 11: Global Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033
Figure 12: Global Market Value (US$ Million) Analysis by Method, 2018 to 2033
Figure 13: Global Market Value Share (%) and BPS Analysis by Method, 2023 to 2033
Figure 14: Global Market Y-o-Y Growth (%) Projections by Method, 2023 to 2033
Figure 15: Global Market Value (US$ Million) Analysis by Pathogen , 2018 to 2033
Figure 16: Global Market Value Share (%) and BPS Analysis by Pathogen , 2023 to 2033
Figure 17: Global Market Y-o-Y Growth (%) Projections by Pathogen , 2023 to 2033
Figure 18: Global Market Value (US$ Million) Analysis by Technology, 2018 to 2033
Figure 19: Global Market Value Share (%) and BPS Analysis by Technology, 2023 to 2033
Figure 20: Global Market Y-o-Y Growth (%) Projections by Technology, 2023 to 2033
Figure 21: Global Market Attractiveness by Product Type, 2023 to 2033
Figure 22: Global Market Attractiveness by Method, 2023 to 2033
Figure 23: Global Market Attractiveness by Pathogen , 2023 to 2033
Figure 24: Global Market Attractiveness by Technology, 2023 to 2033
Figure 25: Global Market Attractiveness by Region, 2023 to 2033
Figure 26: North America Market Value (US$ Million) by Product Type, 2023 to 2033
Figure 27: North America Market Value (US$ Million) by Method, 2023 to 2033
Figure 28: North America Market Value (US$ Million) by Pathogen , 2023 to 2033
Figure 29: North America Market Value (US$ Million) by Technology, 2023 to 2033
Figure 30: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by Product Type, 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033
Figure 37: North America Market Value (US$ Million) Analysis by Method, 2018 to 2033
Figure 38: North America Market Value Share (%) and BPS Analysis by Method, 2023 to 2033
Figure 39: North America Market Y-o-Y Growth (%) Projections by Method, 2023 to 2033
Figure 40: North America Market Value (US$ Million) Analysis by Pathogen , 2018 to 2033
Figure 41: North America Market Value Share (%) and BPS Analysis by Pathogen , 2023 to 2033
Figure 42: North America Market Y-o-Y Growth (%) Projections by Pathogen , 2023 to 2033
Figure 43: North America Market Value (US$ Million) Analysis by Technology, 2018 to 2033
Figure 44: North America Market Value Share (%) and BPS Analysis by Technology, 2023 to 2033
Figure 45: North America Market Y-o-Y Growth (%) Projections by Technology, 2023 to 2033
Figure 46: North America Market Attractiveness by Product Type, 2023 to 2033
Figure 47: North America Market Attractiveness by Method, 2023 to 2033
Figure 48: North America Market Attractiveness by Pathogen , 2023 to 2033
Figure 49: North America Market Attractiveness by Technology, 2023 to 2033
Figure 50: North America Market Attractiveness by Country, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) by Product Type, 2023 to 2033
Figure 52: Latin America Market Value (US$ Million) by Method, 2023 to 2033
Figure 53: Latin America Market Value (US$ Million) by Pathogen , 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) by Technology, 2023 to 2033
Figure 55: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 56: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 57: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 58: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 59: Latin America Market Value (US$ Million) Analysis by Product Type, 2018 to 2033
Figure 60: Latin America Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033
Figure 61: Latin America Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033
Figure 62: Latin America Market Value (US$ Million) Analysis by Method, 2018 to 2033
Figure 63: Latin America Market Value Share (%) and BPS Analysis by Method, 2023 to 2033
Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Method, 2023 to 2033
Figure 65: Latin America Market Value (US$ Million) Analysis by Pathogen , 2018 to 2033
Figure 66: Latin America Market Value Share (%) and BPS Analysis by Pathogen , 2023 to 2033
Figure 67: Latin America Market Y-o-Y Growth (%) Projections by Pathogen , 2023 to 2033
Figure 68: Latin America Market Value (US$ Million) Analysis by Technology, 2018 to 2033
Figure 69: Latin America Market Value Share (%) and BPS Analysis by Technology, 2023 to 2033
Figure 70: Latin America Market Y-o-Y Growth (%) Projections by Technology, 2023 to 2033
Figure 71: Latin America Market Attractiveness by Product Type, 2023 to 2033
Figure 72: Latin America Market Attractiveness by Method, 2023 to 2033
Figure 73: Latin America Market Attractiveness by Pathogen , 2023 to 2033
Figure 74: Latin America Market Attractiveness by Technology, 2023 to 2033
Figure 75: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 76: Europe Market Value (US$ Million) by Product Type, 2023 to 2033
Figure 77: Europe Market Value (US$ Million) by Method, 2023 to 2033
Figure 78: Europe Market Value (US$ Million) by Pathogen , 2023 to 2033
Figure 79: Europe Market Value (US$ Million) by Technology, 2023 to 2033
Figure 80: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 81: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 82: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 83: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 84: Europe Market Value (US$ Million) Analysis by Product Type, 2018 to 2033
Figure 85: Europe Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033
Figure 86: Europe Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033
Figure 87: Europe Market Value (US$ Million) Analysis by Method, 2018 to 2033
Figure 88: Europe Market Value Share (%) and BPS Analysis by Method, 2023 to 2033
Figure 89: Europe Market Y-o-Y Growth (%) Projections by Method, 2023 to 2033
Figure 90: Europe Market Value (US$ Million) Analysis by Pathogen , 2018 to 2033
Figure 91: Europe Market Value Share (%) and BPS Analysis by Pathogen , 2023 to 2033
Figure 92: Europe Market Y-o-Y Growth (%) Projections by Pathogen , 2023 to 2033
Figure 93: Europe Market Value (US$ Million) Analysis by Technology, 2018 to 2033
Figure 94: Europe Market Value Share (%) and BPS Analysis by Technology, 2023 to 2033
Figure 95: Europe Market Y-o-Y Growth (%) Projections by Technology, 2023 to 2033
Figure 96: Europe Market Attractiveness by Product Type, 2023 to 2033
Figure 97: Europe Market Attractiveness by Method, 2023 to 2033
Figure 98: Europe Market Attractiveness by Pathogen , 2023 to 2033
Figure 99: Europe Market Attractiveness by Technology, 2023 to 2033
Figure 100: Europe Market Attractiveness by Country, 2023 to 2033
Figure 101: Asia Pacific Excluding Japan Market Value (US$ Million) by Product Type, 2023 to 2033
Figure 102: Asia Pacific Excluding Japan Market Value (US$ Million) by Method, 2023 to 2033
Figure 103: Asia Pacific Excluding Japan Market Value (US$ Million) by Pathogen , 2023 to 2033
Figure 104: Asia Pacific Excluding Japan Market Value (US$ Million) by Technology, 2023 to 2033
Figure 105: Asia Pacific Excluding Japan Market Value (US$ Million) by Country, 2023 to 2033
Figure 106: Asia Pacific Excluding Japan Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 107: Asia Pacific Excluding Japan Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 108: Asia Pacific Excluding Japan Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 109: Asia Pacific Excluding Japan Market Value (US$ Million) Analysis by Product Type, 2018 to 2033
Figure 110: Asia Pacific Excluding Japan Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033
Figure 111: Asia Pacific Excluding Japan Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033
Figure 112: Asia Pacific Excluding Japan Market Value (US$ Million) Analysis by Method, 2018 to 2033
Figure 113: Asia Pacific Excluding Japan Market Value Share (%) and BPS Analysis by Method, 2023 to 2033
Figure 114: Asia Pacific Excluding Japan Market Y-o-Y Growth (%) Projections by Method, 2023 to 2033
Figure 115: Asia Pacific Excluding Japan Market Value (US$ Million) Analysis by Pathogen , 2018 to 2033
Figure 116: Asia Pacific Excluding Japan Market Value Share (%) and BPS Analysis by Pathogen , 2023 to 2033
Figure 117: Asia Pacific Excluding Japan Market Y-o-Y Growth (%) Projections by Pathogen , 2023 to 2033
Figure 118: Asia Pacific Excluding Japan Market Value (US$ Million) Analysis by Technology, 2018 to 2033
Figure 119: Asia Pacific Excluding Japan Market Value Share (%) and BPS Analysis by Technology, 2023 to 2033
Figure 120: Asia Pacific Excluding Japan Market Y-o-Y Growth (%) Projections by Technology, 2023 to 2033
Figure 121: Asia Pacific Excluding Japan Market Attractiveness by Product Type, 2023 to 2033
Figure 122: Asia Pacific Excluding Japan Market Attractiveness by Method, 2023 to 2033
Figure 123: Asia Pacific Excluding Japan Market Attractiveness by Pathogen , 2023 to 2033
Figure 124: Asia Pacific Excluding Japan Market Attractiveness by Technology, 2023 to 2033
Figure 125: Asia Pacific Excluding Japan Market Attractiveness by Country, 2023 to 2033
Figure 126: Japan Market Value (US$ Million) by Product Type, 2023 to 2033
Figure 127: Japan Market Value (US$ Million) by Method, 2023 to 2033
Figure 128: Japan Market Value (US$ Million) by Pathogen , 2023 to 2033
Figure 129: Japan Market Value (US$ Million) by Technology, 2023 to 2033
Figure 130: Japan Market Value (US$ Million) by Country, 2023 to 2033
Figure 131: Japan Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 132: Japan Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 133: Japan Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 134: Japan Market Value (US$ Million) Analysis by Product Type, 2018 to 2033
Figure 135: Japan Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033
Figure 136: Japan Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033
Figure 137: Japan Market Value (US$ Million) Analysis by Method, 2018 to 2033
Figure 138: Japan Market Value Share (%) and BPS Analysis by Method, 2023 to 2033
Figure 139: Japan Market Y-o-Y Growth (%) Projections by Method, 2023 to 2033
Figure 140: Japan Market Value (US$ Million) Analysis by Pathogen , 2018 to 2033
Figure 141: Japan Market Value Share (%) and BPS Analysis by Pathogen , 2023 to 2033
Figure 142: Japan Market Y-o-Y Growth (%) Projections by Pathogen , 2023 to 2033
Figure 143: Japan Market Value (US$ Million) Analysis by Technology, 2018 to 2033
Figure 144: Japan Market Value Share (%) and BPS Analysis by Technology, 2023 to 2033
Figure 145: Japan Market Y-o-Y Growth (%) Projections by Technology, 2023 to 2033
Figure 146: Japan Market Attractiveness by Product Type, 2023 to 2033
Figure 147: Japan Market Attractiveness by Method, 2023 to 2033
Figure 148: Japan Market Attractiveness by Pathogen , 2023 to 2033
Figure 149: Japan Market Attractiveness by Technology, 2023 to 2033
Figure 150: Japan Market Attractiveness by Country, 2023 to 2033
Figure 151: Middle East and Africa Market Value (US$ Million) by Product Type, 2023 to 2033
Figure 152: Middle East and Africa Market Value (US$ Million) by Method, 2023 to 2033
Figure 153: Middle East and Africa Market Value (US$ Million) by Pathogen , 2023 to 2033
Figure 154: Middle East and Africa Market Value (US$ Million) by Technology, 2023 to 2033
Figure 155: Middle East and Africa Market Value (US$ Million) by Country, 2023 to 2033
Figure 156: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 157: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 158: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 159: Middle East and Africa Market Value (US$ Million) Analysis by Product Type, 2018 to 2033
Figure 160: Middle East and Africa Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033
Figure 161: Middle East and Africa Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033
Figure 162: Middle East and Africa Market Value (US$ Million) Analysis by Method, 2018 to 2033
Figure 163: Middle East and Africa Market Value Share (%) and BPS Analysis by Method, 2023 to 2033
Figure 164: Middle East and Africa Market Y-o-Y Growth (%) Projections by Method, 2023 to 2033
Figure 165: Middle East and Africa Market Value (US$ Million) Analysis by Pathogen , 2018 to 2033
Figure 166: Middle East and Africa Market Value Share (%) and BPS Analysis by Pathogen , 2023 to 2033
Figure 167: Middle East and Africa Market Y-o-Y Growth (%) Projections by Pathogen , 2023 to 2033
Figure 168: Middle East and Africa Market Value (US$ Million) Analysis by Technology, 2018 to 2033
Figure 169: Middle East and Africa Market Value Share (%) and BPS Analysis by Technology, 2023 to 2033
Figure 170: Middle East and Africa Market Y-o-Y Growth (%) Projections by Technology, 2023 to 2033
Figure 171: Middle East and Africa Market Attractiveness by Product Type, 2023 to 2033
Figure 172: Middle East and Africa Market Attractiveness by Method, 2023 to 2033
Figure 173: Middle East and Africa Market Attractiveness by Pathogen , 2023 to 2033
Figure 174: Middle East and Africa Market Attractiveness by Technology, 2023 to 2033
Figure 175: Middle East and Africa Market Attractiveness by Country, 2023 to 2033
The overall market size for the sepsis diagnostics market was USD 655.7 Million in 2025.
The sepsis diagnostics market is expected to reach USD 1,402.7 Million in 2035.
The demand for sepsis diagnostics is rising due to increasing global sepsis incidence, growing awareness of early detection, and advancements in automated diagnostic tools. Rapid identification of bloodstream infections and improved clinical outcomes through early intervention are further fueling market growth.
The top 5 countries driving the development of the sepsis diagnostics market are the USA, Germany, China, Japan, and the UK
Instruments and automated diagnostics are expected to command a significant share over the assessment period.
Explore Similar Insights
Sepsis Diagnostics Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
